Literature DB >> 15544577

A phenotypic and molecular characterization of the fmr1-tm1Cgr fragile X mouse.

Q J Yan1, P K Asafo-Adjei, H M Arnold, R E Brown, R P Bauchwitz.   

Abstract

Fragile X Syndrome is the most common form of inherited mental retardation. It is also known for having a substantial behavioral morbidity, including autistic features. In humans, Fragile X Syndrome is almost always caused by inactivation of the X-linked FMR1 gene. A single knockout mouse model, fmr1-tm1Cgr, exists. In this report we further characterize the cognitive and behavioral phenotype of the fmr1-tm1Cgr Fragile X mouse through the use of F1 hybrid mice derived from two inbred strains (FVB/NJ and C57BL/6J). Use of F1 hybrids allows focus on the effects of the fmr1-tm1Cgr allele with reduced influence from recessive alleles present in the parental inbred strains. We find that the cognitive phenotype of fmr1-tm1Cgr mice, including measures of working memory and learning set formation that are known to be seriously impacted in humans with Fragile X Syndrome, are essentially normal. Further testing of inbred strains supports this conclusion. Thus, any fmr1-tm1Cgr cognitive deficit is surprisingly mild or absent. There is, however, clear support presented for a robust audiogenic seizure phenotype in all strains tested, as well as increased entries into the center of an open field. Finally, a molecular examination of the fmr1-tm1Cgr mouse shows that, contrary to common belief, it is not a molecular null. Implications of this finding for interpretation of the phenotype are discussed.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15544577     DOI: 10.1111/j.1601-183X.2004.00087.x

Source DB:  PubMed          Journal:  Genes Brain Behav        ISSN: 1601-183X            Impact factor:   3.449


  85 in total

1.  Extinction of an instrumental response: a cognitive behavioral assay in Fmr1 knockout mice.

Authors:  M S Sidorov; D D Krueger; M Taylor; E Gisin; E K Osterweil; M F Bear
Journal:  Genes Brain Behav       Date:  2014-04-30       Impact factor: 3.449

Review 2.  Fragile X syndrome and targeted treatment trials.

Authors:  Randi Hagerman; Julie Lauterborn; Jacky Au; Elizabeth Berry-Kravis
Journal:  Results Probl Cell Differ       Date:  2012

3.  Comprehensive motor testing in Fmr1-KO mice exposes temporal defects in oromotor coordination.

Authors:  Snigdha Roy; Yu Zhao; Melody Allensworth; Mohamed F Farook; Mark S LeDoux; Lawrence T Reiter; Detlef H Heck
Journal:  Behav Neurosci       Date:  2011-10-17       Impact factor: 1.912

4.  The GABA(A) receptor agonist THIP ameliorates specific behavioral deficits in the mouse model of fragile X syndrome.

Authors:  Jose Luis Olmos-Serrano; Joshua G Corbin; Mark P Burns
Journal:  Dev Neurosci       Date:  2011-11-08       Impact factor: 2.984

5.  Olfactory discrimination learning in mice lacking the fragile X mental retardation protein.

Authors:  John Larson; Daniel Kim; Roseanne C Patel; Christina Floreani
Journal:  Neurobiol Learn Mem       Date:  2008-03-04       Impact factor: 2.877

Review 6.  The fragile X mental retardation protein in circadian rhythmicity and memory consolidation.

Authors:  Cheryl L Gatto; Kendal Broadie
Journal:  Mol Neurobiol       Date:  2009-02-12       Impact factor: 5.590

7.  Elevated glycogen synthase kinase-3 activity in Fragile X mice: key metabolic regulator with evidence for treatment potential.

Authors:  Wenzhong William Min; Christopher J Yuskaitis; Qijiang Yan; Christopher Sikorski; Shengqiang Chen; Richard S Jope; Robert P Bauchwitz
Journal:  Neuropharmacology       Date:  2008-10-14       Impact factor: 5.250

8.  Environmental enrichment reveals effects of genotype on hippocampal spine morphologies in the mouse model of Fragile X Syndrome.

Authors:  Julie C Lauterborn; Matiar Jafari; Alex H Babayan; Christine M Gall
Journal:  Cereb Cortex       Date:  2013-09-17       Impact factor: 5.357

9.  Glycogen synthase kinase-3 inhibitors reverse deficits in long-term potentiation and cognition in fragile X mice.

Authors:  Aimee V Franklin; Margaret K King; Valle Palomo; Ana Martinez; Lori L McMahon; Richard S Jope
Journal:  Biol Psychiatry       Date:  2013-09-13       Impact factor: 13.382

Review 10.  Oxytocin and vasopressin systems in genetic syndromes and neurodevelopmental disorders.

Authors:  S M Francis; A Sagar; T Levin-Decanini; W Liu; C S Carter; S Jacob
Journal:  Brain Res       Date:  2014-01-22       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.